China's medical products administrator approved ApicHope Pharmaceutical's (SHE:300723) Levocarnitine oral solution, according to a Monday filing with the Shenzhen bourse.
The product treats primary systemic carnitine deficiency shown in Reye's encephalopathy or a rare swelling in the liver or the brain, hypoketotic hypoglycemia or low blood sugar and ketones, and/or cardiomyopathy or difficulty in heart pumping, the filing said.
Shares jumped 2% during morning trading on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments